A cooperative study was conducted to determine the efficacy of 30 days of treatment with either a glucocorticosteroid (prednisolone) or an anabolic steroid (oxandrolone) in moderate or severe alcoholic hepatitis. One hundred thirty-two patients with moderate disease and 131 with severe disease were randomly assigned to one of three treatments: prednisolone, oxandrolone, or placebo. During the 30 days, mortality in the groups receiving steroid therapy was not significantly different from mortality in the placebo group. Thirteen per cent of the moderately ill patients and 29 per cent of the severely ill patients died. Although neither steroid improved short-term survival, oxandrolone therapy was associated with a beneficial effect on long-term survival. This was especially true in patients with moderate disease: among those who survived for one or two months after the start of treatment the conditional six-month death rate was 3.5 per cent after oxandrolone and 19 to 20 per cent after placebo (P = 0.02). No consistent long-term effect was associated with prednisolone therapy.
This article has been cited by other articles:
Lucey, M. R., Mathurin, P., Morgan, T. R.
(2009). Alcoholic Hepatitis. NEJM
360: 2758-2769
[Full Text]
Guha, I N, Rosenberg, W M
(2006). Future use of the Glasgow alcoholic hepatitis score. Gut
55: 135-136
[Full Text]
Forrest, E H, Evans, C D J, Stewart, S, Phillips, M, Oo, Y H, McAvoy, N C, Fisher, N C, Singhal, S, Brind, A, Haydon, G, O'Grady, J, Day, C P, Hayes, P C, Murray, L S, Morris, A J
(2005). Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow alcoholic hepatitis score. Gut
54: 1174-1179
[Abstract][Full Text]
Javaheri, S., Almoosa, K. F., Saleh, K., Mendenhall, C. L.
(2005). Hypocapnia Is Not a Predictor of Central Sleep Apnea in Patients with Cirrhosis. Am. J. Respir. Crit. Care Med.
171: 908-911
[Abstract][Full Text]
Madhotra, R., Gilmore, I.T.
(2003). Recent developments in the treatment of alcoholic hepatitis. QJM
96: 391-400
[Abstract][Full Text]
Basaria, S., Wahlstrom, J. T., Dobs, A. S.
(2001). Anabolic-Androgenic Steroid Therapy in the Treatment of Chronic Diseases. J. Clin. Endocrinol. Metab.
86: 5108-5117
[Abstract][Full Text]
Devlin, J, O'Grady, J
(1999). Indications for referral and assessment in adultliver transplantation: a clinical guideline. Gut
45: VI1-22
[Full Text]
Strawford, A., Barbieri, T., Van Loan, M., Parks, E., Catlin, D., Barton, N., Neese, R., Christiansen, M., King, J., Hellerstein, M. K.
(1999). Resistance Exercise and Supraphysiologic Androgen Therapy in Eugonadal Men With HIV-Related Weight Loss: A Randomized Controlled Trial. JAMA
281: 1282-1290
[Abstract][Full Text]
Lieber, C. S.
(1995). Medical Disorders of Alcoholism. NEJM
333: 1058-1065
[Full Text]
Imperiale, T. F., McCullough, A. J.
(1990). Do Corticosteroids Reduce Mortality from Alcoholic Hepatitis? A Meta-analysis of the Randomized Trials. ANN INTERN MED
113: 299-307
[Abstract]
Carithers, R. L. Jr., Herlong, H. F., Diehl, A. M., Shaw, E. W., Combes, B., Fallon, H. J., Maddrey, W. C.
(1989). Methylprednisolone Therapy in Patients with Severe Alcoholic Hepatitis: A Randomized Multicenter Trial. ANN INTERN MED
110: 685-690
[Abstract]
Mendenhall, C., Bongiovanni, G., Goldberg, S., Miller, B., Moore, J., Rouster, S., Schneider, D., Tamburro, C., Tosch, T., Weesner, R., VA COOPERATIVE STUDY GROUP ON ALCOHOLIC HEPATITIS,
(1985). VA Cooperative Study on Alcoholic Hepatitis III: Changes in Protein-Calorie Malnutrition Associated with 30 Days of Hospitalization with and without Enteral Nutritional Therapy. JPEN J Parenter Enteral Nutr
9: 590-596
[Abstract]
Previous
